Slingshot members are tracking this event:
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 08, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda Clearance, Ind, Zfn-media Genome, Sb-318, Sb-318-1502, Mucopolysaccharidosis Type I